Red Spruce Capital
ABBV icon

Red Spruce Capital’s AbbVie ABBV Stock Holding History

Red Spruce Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.7M Buy
44,565
+99
+0.2% +$25.4K 4.12% 2
2026
Q2 		$11.2M Buy
44,466
+8
+0% +$1.72K 3.9% 3
2026
Q1 		$9.7M Buy
44,458
+174
+0.4% +$38.6K 3.97% 4
2025
Q4 		$10.1M Sell
44,284
-112
-0.3% -$25.5K 4.03% 4
2025
Q3 		$10.3M Sell
44,396
-353
-0.8% -$71.9K 4.19% 3
2025
Q2 		$8.31M Sell
44,749
-1,079
-2% -$201K 3.6% 4
2025
Q1 		$9.6M Sell
45,828
-6,997
-13% -$1.36M 4.52% 4
2024
Q4 		$9.39M Buy
52,825
+77
+0.1% +$14.2K 4.17% 3
2024
Q3 		$10.4M Sell
52,748
-748
-1% -$140K 4.74% 3
2024
Q2 		$9.18M Buy
53,496
+3,816
+8% +$632K 4.26% 4
2024
Q1 		$9.05M Buy
49,680
+62
+0.1% +$10.7K 4.2% 4
2023
Q4 		$7.69M Buy
49,618
+488
+1% +$71.1K 3.95% 3
2023
Q3 		$7.32M Sell
49,130
-22
-0% -$3.23K 4.16% 4
2023
Q2 		$6.62M Buy
49,152
+10,162
+26% +$1.49M 3.57% 5
2023
Q1 		$6.21M Buy
38,990
+261
+0.7% +$39.9K 3.64% 5
2022
Q4 		$6.26M Sell
38,729
-103
-0.3% -$15.8K 3.98% 4
2022
Q3 		$5.21M Sell
38,832
-2,627
-6% -$377K 3.66% 4
2022
Q2 		$6.35M Sell
41,459
-716
-2% -$109K 4.23% 4
2022
Q1 		$6.84M Sell
42,175
-550
-1% -$79.9K 3.88% 4
2021
Q4 		$5.78M Buy
42,725
+150
+0.4% +$17.7K 3.16% 4
2021
Q3 		$4.59M Buy
42,575
+564
+1% +$64.4K 2.69% 8
2021
Q2 		$4.73M Sell
42,011
-224
-0.5% -$25.2K 2.79% 7
2021
Q1 		$4.57M Buy
42,235
+990
+2% +$106K 2.91% 6
2020
Q4 		$4.42M Buy
41,245
+930
+2% +$89.4K 3.07% 5
2020
Q3 		$3.53M Buy
40,315
+123
+0.3% +$11.6K 2.87% 7
2020
Q2 		$3.95M Sell
40,192
-429
-1% -$37.8K 3.35% 5
2020
Q1 		$3.1M Buy
40,621
+5,984
+17% +$510K 3.22% 6
2019
Q4 		$3.07M Buy
+34,637
New +$2.88M 2.56% 8

Other funds holding ABBV

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Cardano Risk Management
Cardano Risk Management Rotterdam, Netherlands $18.2B AUM 38.97% 1-Year Est. Return
Hamlin Capital Management
Hamlin Capital Management New York $4.04B AUM 11.59% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Ferguson Wellman Capital Management
Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return
ABN AMRO Investment Solutions
ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Red Spruce Capital's ABBV Position: Q3 2026 in Review

Red Spruce Capital increased its AbbVie (ABBV) stake by 0.22% in Q3 2026, buying an estimated $25.4K and bringing the position to 44,565 shares worth $11.7M. The position accounts for 4.12% of the portfolio, ranked #2.

Red Spruce Capital first reported a position in ABBV in Q4 2019 and has held it in 28 quarters since. 1,209 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Red Spruce Capital held 44,565 shares of AbbVie worth $11.7M as of Q3 2026.
  • Red Spruce Capital bought 99 AbbVie shares in Q3 2026, an estimated $25.4K.
  • AbbVie made up 4.12% of Red Spruce Capital's portfolio in Q3 2026, its #2 holding.
  • Red Spruce Capital first reported a position in AbbVie in Q4 2019 and has held it in 28 quarters since.
  • 1,209 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Red Spruce Capital's 13F filing for Q3 2026, filed 7 Oct 2026.